BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Patel K, Gordon SC, Jacobson I, Hézode C, Oh E, Smith KM, Pawlotsky JM, McHutchison JG. Evaluation of a panel of non-invasive serum markers to differentiate mild from moderate-to-advanced liver fibrosis in chronic hepatitis C patients. J Hepatol 2004;41:935-42. [PMID: 15582126 DOI: 10.1016/j.jhep.2004.08.008] [Cited by in Crossref: 243] [Cited by in F6Publishing: 241] [Article Influence: 12.8] [Reference Citation Analysis]
Number Citing Articles
1 Pérez-Is L, Collazos J, de la Fuente B, Morano L, Rivas-Carmenado M, Rodriguez M, Romero-Favela A, Fonseca-González GJ, Melón S, Valle-Garay E, Asensi V. 24-month decline of non-invasive liver fibrosis markers in HCV-mono and HCV/HIV coinfection after direct-acting antiviral therapy. Sci Rep 2022;12:3828. [PMID: 35264591 DOI: 10.1038/s41598-022-07548-y] [Reference Citation Analysis]
2 Martinou E, Pericleous M, Stefanova I, Kaur V, Angelidi AM. Diagnostic Modalities of Non-Alcoholic Fatty Liver Disease: From Biochemical Biomarkers to Multi-Omics Non-Invasive Approaches. Diagnostics (Basel) 2022;12:407. [PMID: 35204498 DOI: 10.3390/diagnostics12020407] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 10.0] [Reference Citation Analysis]
3 Kaur N, Goyal G, Garg R, Tapasvi C, Chawla S, Kaur R. Potential role of noninvasive biomarkers during liver fibrosis. World J Hepatol 2021; 13(12): 1919-1935 [DOI: 10.4254/wjh.v13.i12.1919] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Rewisha E, Salman T, Alhaddad O, Raia GA, Naguib M, Rashad S, Abdelfattah A, Metwally K, Abdelsameea E. Hyaluronic acid as a potential marker for assessment of fibrosis regression after direct acting antiviral drugs in chronic hepatitis C patients. Clin Exp Hepatol 2021;7:320-7. [PMID: 34712835 DOI: 10.5114/ceh.2021.109293] [Reference Citation Analysis]
5 Singh A, Ranjan V, Das R, Bhatti K, Mehta DK, Chidurala RM. Serum Biomarkers for Noninvasive Diagnosis of Liver Diseases: How Laudable are These Tools? CCB 2021;15:128-138. [DOI: 10.2174/2212796814999201111204639] [Reference Citation Analysis]
6 Guerra-ruiz AR, Casals G, Iruzubieta P, Lalana M, Leis A, López RM, Crespo J, Morales-ruiz M. Valoración bioquímica en la enfermedad hepática grasa asociada a la disfunción metabólica. Advances in Laboratory Medicine / Avances en Medicina de Laboratorio 2021;2:209-219. [DOI: 10.1515/almed-2020-0062] [Reference Citation Analysis]
7 Guerra-ruiz AR, Casals G, Iruzubieta P, Lalana M, Leis A, López RM, Crespo J, Morales-ruiz M. Biochemical assessment of metabolic associated fatty liver disease. Advances in Laboratory Medicine / Avances en Medicina de Laboratorio 2021;2:199-208. [DOI: 10.1515/almed-2021-0009] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Du J. Research on Hepatitis Auxiliary Diagnosis Based on Random Forest and Support Vector Machine. 2021 2nd International Conference on Computing and Data Science (CDS) 2021. [DOI: 10.1109/cds52072.2021.00041] [Reference Citation Analysis]
9 Castera L. Assessment of Liver Disease Severity. Hepatitis C: Care and Treatment 2021. [DOI: 10.1007/978-3-030-67762-6_1] [Reference Citation Analysis]
10 Paul J. Recent advances in non-invasive diagnosis and medical management of non-alcoholic fatty liver disease in adult. Egypt Liver Journal 2020;10. [DOI: 10.1186/s43066-020-00043-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
11 Loomba R, Adams LA. Advances in non-invasive assessment of hepatic fibrosis. Gut 2020;69:1343-52. [PMID: 32066623 DOI: 10.1136/gutjnl-2018-317593] [Cited by in Crossref: 106] [Cited by in F6Publishing: 89] [Article Influence: 35.3] [Reference Citation Analysis]
12 Joseph J. Serum Marker Panels for Predicting Liver Fibrosis - An Update. Clin Biochem Rev 2020;41:67-73. [PMID: 32518428 DOI: 10.33176/AACB-20-00002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
13 Wang Y, Pan W, Zhao D, Chen Y, Chen X, Xia H. Diagnostic Value of Serum Procollagen III N-Terminal Peptide for Liver Fibrosis in Infantile Cholestasis. Front Pediatr 2020;8:131. [PMID: 32296668 DOI: 10.3389/fped.2020.00131] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
14 Suri J, Curry MP. Liver biopsy in chronic viral hepatitis: is there still life left in it? Clinical Dilemmas in Viral Liver Disease 2020. [DOI: 10.1002/9781119533481.ch2] [Reference Citation Analysis]
15 Patel K, Sebastiani G. Limitations of non-invasive tests for assessment of liver fibrosis. JHEP Rep. 2020;2:100067. [PMID: 32118201 DOI: 10.1016/j.jhepr.2020.100067] [Cited by in Crossref: 68] [Cited by in F6Publishing: 73] [Article Influence: 22.7] [Reference Citation Analysis]
16 Shiha G, Mousa N. Noninvasive Biomarkers for Liver Fibrosis. Liver Diseases 2020. [DOI: 10.1007/978-3-030-24432-3_36] [Reference Citation Analysis]
17 Ahmed Y, Hussein RS, Basha TA, Khalifa AM, Ibrahim AS, Abdelmoaty AS, Abdella HM, Fahmy AS. Detecting liver fibrosis using a machine learning-based approach to the quantification of the heart-induced deformation in tagged MR images. NMR Biomed. 2020;33:e4215. [PMID: 31730265 DOI: 10.1002/nbm.4215] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
18 Castera L. Noninvasive Tests of Liver Fibrosis. Evidence-based Gastroenterology and Hepatology 4e 2019. [DOI: 10.1002/9781119211419.ch30] [Reference Citation Analysis]
19 Camarata MA, Weiss KH, Schilsky ML. Special Treatment Considerations for Wilson Disease. Wilson Disease 2019. [DOI: 10.1016/b978-0-12-811077-5.00023-2] [Reference Citation Analysis]
20 Day J, Patel P, Parkes J, Rosenberg W. Derivation and Performance of Standardized Enhanced Liver Fibrosis (ELF) Test Thresholds for the Detection and Prognosis of Liver Fibrosis. J Appl Lab Med. 2019;3:815-826. [PMID: 31639756 DOI: 10.1373/jalm.2018.027359] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]
21 Rostved AA, Ostrowski SR, Peters L, Lundgren JD, Hillingsø J, Johansson PI, Rasmussen A. Hyaluronic Acid Is a Biomarker for Allograft Dysfunction and Predicts 1-Year Graft Loss After Liver Transplantation. Transplant Proc 2018;50:3635-43. [PMID: 30577249 DOI: 10.1016/j.transproceed.2018.09.018] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
22 Navrotsky AN. [Diagnostic possibilities of methods for the evaluation of liver fibrosis in chronic viral hepatitis]. Ter Arkh 2016;88:149-55. [PMID: 28635835 DOI: 10.17116/terarkh20168811149-155] [Reference Citation Analysis]
23 Majumdar A, Pinzani M. Non-invasive Assessment of Fibrosis and Cirrhosis. Sherlock's Diseases of the Liver and Biliary System 2018. [DOI: 10.1002/9781119237662.ch7] [Reference Citation Analysis]
24 Zeremski M, Martinez A. Liver Disease and Fibrosis Assessment in Substance Use-Related Disorders. Clin Pharmacol Drug Dev 2017;6:164-8. [PMID: 28263455 DOI: 10.1002/cpdd.312] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
25 Wang XC, Zhang XY, Zhang X, Yuan ZX, Li XH, Wang JC, Sun B, Lu XJ. Pitfalls in the non-invasive assessment of liver fibrosis with eLIFT-FM(VCTE) algorithm. J Hepatol 2018;68:602-3. [PMID: 28993184 DOI: 10.1016/j.jhep.2017.08.038] [Reference Citation Analysis]
26 Lambrecht J, Verhulst S, Mannaerts I, Reynaert H, van Grunsven LA. Prospects in non-invasive assessment of liver fibrosis: Liquid biopsy as the future gold standard? Biochim Biophys Acta Mol Basis Dis. 2018;1864:1024-1036. [PMID: 29329986 DOI: 10.1016/j.bbadis.2018.01.009] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 5.4] [Reference Citation Analysis]
27 Tapper EB, Afdhal NH. Noninvasive Assessment of Disease Progression. Zakim and Boyer's Hepatology 2018. [DOI: 10.1016/b978-0-323-37591-7.00008-2] [Reference Citation Analysis]
28 Liu CH, Liu CJ, Hong CM, Su TH, Yang HC, Chen KM, Huang YP, Yeh YM, Tien HL, Liu YC, Kao JH, Chen DS, Chen PJ. A noninvasive diagnosis of hepatic fibrosis by BioFibroScore® in chronic hepatitis C patients. J Gastroenterol Hepatol 2018;33:291-7. [PMID: 28548299 DOI: 10.1111/jgh.13834] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
29 Nallagangula KS, Nagaraj SK, Venkataswamy L, Chandrappa M. Liver fibrosis: a compilation on the biomarkers status and their significance during disease progression. Future Sci OA 2018;4:FSO250. [PMID: 29255622 DOI: 10.4155/fsoa-2017-0083] [Cited by in Crossref: 68] [Cited by in F6Publishing: 73] [Article Influence: 11.3] [Reference Citation Analysis]
30 Kang J, Lee M. Noninvasive Diagnostic and Prognostic Assessment Tools for Liver Fibrosis and Cirrhosis in Patients with Chronic Liver Disease. Liver Cirrhosis - Update and Current Challenges 2017. [DOI: 10.5772/intechopen.68317] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
31 Collazos J, Valle-Garay E, Suárez-Zarracina T, Montes AH, Cartón JA, Asensi V. Matrix metalloproteases and their tissue inhibitors in non-alcoholic liver fibrosis of human immunodeficiency virus-infected patients. World J Virol 2017; 6(2): 36-45 [PMID: 28573088 DOI: 10.5501/wjv.v6.i2.36] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
32 Mikołajczyk-Korniak N, Tronina O, Ślubowska K, Perkowska-Ptasińska A, Pacholczyk M, Bączkowska T, Durlik M. Dynamic Elastography in Diagnostics of Liver Fibrosis in Patients After Liver Transplantation Due to Cirrhosis in the Course of Hepatitis C. Transplant Proc 2016;48:1725-9. [PMID: 27496480 DOI: 10.1016/j.transproceed.2016.01.081] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
33 Tanwar S, Trembling PM, Hogan BJ, Srivastava A, Parkes J, Harris S, Grant P, Nastouli E, Ocker M, Wehr K, Herold C, Neureiter D, Schuppan D, Rosenberg WM. Noninvasive markers of liver fibrosis: on-treatment changes of serum markers predict the outcome of antifibrotic therapy. Eur J Gastroenterol Hepatol 2017;29:289-96. [PMID: 27906753 DOI: 10.1097/MEG.0000000000000789] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
34 Tanwar S, Trembling PM, Hogan BJ, Parkes J, Harris S, Grant P, Nastouli E, Ocker M, Wehr K, Herold C, Neureiter D, Schuppan D, Rosenberg WM. Biomarkers of Hepatic Fibrosis in Chronic Hepatitis C: A Comparison of 10 Biomarkers Using 2 Different Assays for Hyaluronic Acid. J Clin Gastroenterol 2017;51:268-77. [PMID: 27380461 DOI: 10.1097/MCG.0000000000000581] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
35 Mak KM, Mei R. Basement Membrane Type IV Collagen and Laminin: An Overview of Their Biology and Value as Fibrosis Biomarkers of Liver Disease. Anat Rec (Hoboken). 2017;300:1371-1390. [PMID: 28187500 DOI: 10.1002/ar.23567] [Cited by in Crossref: 117] [Cited by in F6Publishing: 122] [Article Influence: 19.5] [Reference Citation Analysis]
36 Huang Y, Jeffrey GP, Adams LA. Hepascore and Its Application to Liver Disease. Biomarkers in Disease: Methods, Discoveries and Applications 2017. [DOI: 10.1007/978-94-007-7675-3_29] [Reference Citation Analysis]
37 Colli A, Fraquelli M, Prati D, Riva A, Berzuini A, Conte D, Aghemo A, Colombo M, Casazza G. Deciding on Interferon-Free Treatment for Chronic Hepatitis C: Updating Liver Stiffness Cut-Off Values to Maximize Benefit. PLoS One 2016;11:e0164452. [PMID: 27723770 DOI: 10.1371/journal.pone.0164452] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
38 Qi X, Liu X, Zhang Y, Hou Y, Ren L, Wu C, Chen J, Xia C, Zhao J, Wang D, Zhang Y, Zhang X, Lin H, Wang H, Wang J, Cui Z, Li X, Deng H, Hou F, Peng Y, Wang X, Shao X, Li H, Guo X. Serum Liver Fibrosis Markers in the Prognosis of Liver Cirrhosis: A Prospective Observational Study. Med Sci Monit 2016;22:2720-30. [PMID: 27480906 DOI: 10.12659/msm.900441] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
39 Cui J, Philo L, Nguyen P, Hofflich H, Hernandez C, Bettencourt R, Richards L, Salotti J, Bhatt A, Hooker J, Haufe W, Hooker C, Brenner DA, Sirlin CB, Loomba R. Sitagliptin vs. placebo for non-alcoholic fatty liver disease: A randomized controlled trial. J Hepatol 2016;65:369-76. [PMID: 27151177 DOI: 10.1016/j.jhep.2016.04.021] [Cited by in Crossref: 219] [Cited by in F6Publishing: 214] [Article Influence: 31.3] [Reference Citation Analysis]
40 Bracht T, Mölleken C, Ahrens M, Poschmann G, Schlosser A, Eisenacher M, Stühler K, Meyer HE, Schmiegel WH, Holmskov U, Sorensen GL, Sitek B. Evaluation of the biomarker candidate MFAP4 for non-invasive assessment of hepatic fibrosis in hepatitis C patients. J Transl Med 2016;14:201. [PMID: 27378383 DOI: 10.1186/s12967-016-0952-3] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 4.1] [Reference Citation Analysis]
41 Morling JR, Guha IN. Biomarkers of liver fibrosis. Clin Liver Dis (Hoboken) 2016;7:139-42. [PMID: 31041049 DOI: 10.1002/cld.555] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
42 Chin JL, Pavlides M, Moolla A, Ryan JD. Non-invasive Markers of Liver Fibrosis: Adjuncts or Alternatives to Liver Biopsy? Front Pharmacol. 2016;7:159. [PMID: 27378924 DOI: 10.3389/fphar.2016.00159] [Cited by in Crossref: 38] [Cited by in F6Publishing: 43] [Article Influence: 5.4] [Reference Citation Analysis]
43 Almpanis Z, Demonakou M, Tiniakos D. Evaluation of liver fibrosis: "Something old, something new…". Ann Gastroenterol 2016;29:445-53. [PMID: 27708509 DOI: 10.20524/aog.2016.0046] [Cited by in Crossref: 11] [Cited by in F6Publishing: 19] [Article Influence: 1.6] [Reference Citation Analysis]
44 Babaei Z, Parsian H. Hyaluronic acid algorithm-based models for assessment of liver fibrosis: translation from basic science to clinical application. Hepatobiliary Pancreat Dis Int 2016;15:131-40. [PMID: 27020628 DOI: 10.1016/s1499-3872(16)60062-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
45 Zhu Q, Li N, Li F, Zhou Z, Han Q, Lv Y, Sang J, Liu Z. Therapeutic effect of renin angiotensin system inhibitors on liver fibrosis. J Renin Angiotensin Aldosterone Syst. 2016;17:1470320316628717. [PMID: 27009285 DOI: 10.1177/1470320316628717] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 3.4] [Reference Citation Analysis]
46 Xiao G, Yan L. Liver Fibrosis and Its Assessment. Operative Techniques in Liver Resection 2016. [DOI: 10.1007/978-94-017-7411-6_5] [Reference Citation Analysis]
47 Sheiko MA, Rosen HR. Hepatic Fibrosis in Hepatitis C. Hepatitis C Virus II 2016. [DOI: 10.1007/978-4-431-56101-9_3] [Reference Citation Analysis]
48 Rockey DC. Hepatic Fibrosis and Cirrhosis. Yamada' s Textbook of Gastroenterology 2015. [DOI: 10.1002/9781118512074.ch105] [Reference Citation Analysis]
49 European Association for Study of Liver, Asociacion Latinoamericana para el Estudio del Higado. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol 2015;63:237-64. [PMID: 25911335 DOI: 10.1016/j.jhep.2015.04.006] [Cited by in Crossref: 1128] [Cited by in F6Publishing: 1122] [Article Influence: 141.0] [Reference Citation Analysis]
50 Enomoto H, Bando Y, Nakamura H, Nishiguchi S, Koga M. Liver fibrosis markers of nonalcoholic steatohepatitis. World J Gastroenterol 2015; 21(24): 7427-7435 [PMID: 26139988 DOI: 10.3748/wjg.v21.i24.7427] [Cited by in CrossRef: 41] [Cited by in F6Publishing: 42] [Article Influence: 5.1] [Reference Citation Analysis]
51 Enomoto H, Aizawa N, Nakamura H, Takata R, Sakai Y, Iwata Y, Tanaka H, Ikeda N, Aoki T, Hasegawa K, Yoh K, Hashimoto K, Ishii A, Takashima T, Saito M, Imanishi H, Iijima H, Nishiguchi S. A new metabolism-related index correlates with the degree of liver fibrosis in hepatitis C virus-positive patients. Gastroenterol Res Pract 2015;2015:926169. [PMID: 25861264 DOI: 10.1155/2015/926169] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
52 Park SH, Bang CS, Kim DJ. Biomarkers in HCV Infection. Adv Clin Chem 2015;70:131-96. [PMID: 26231487 DOI: 10.1016/bs.acc.2015.03.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
53 Bracht T, Schweinsberg V, Trippler M, Kohl M, Ahrens M, Padden J, Naboulsi W, Barkovits K, Megger DA, Eisenacher M, Borchers CH, Schlaak JF, Hoffmann A, Weber F, Baba HA, Meyer HE, Sitek B. Analysis of Disease-Associated Protein Expression Using Quantitative Proteomics—Fibulin-5 Is Expressed in Association with Hepatic Fibrosis. J Proteome Res 2015;14:2278-86. [DOI: 10.1021/acs.jproteome.5b00053] [Cited by in Crossref: 51] [Cited by in F6Publishing: 53] [Article Influence: 6.4] [Reference Citation Analysis]
54 Afdhal NH, Bacon BR, Patel K, Lawitz EJ, Gordon SC, Nelson DR, Challies TL, Nasser I, Garg J, Wei LJ, McHutchison JG. Accuracy of fibroscan, compared with histology, in analysis of liver fibrosis in patients with hepatitis B or C: a United States multicenter study. Clin Gastroenterol Hepatol 2015;13:772-9.e1-3. [PMID: 25528010 DOI: 10.1016/j.cgh.2014.12.014] [Cited by in Crossref: 122] [Cited by in F6Publishing: 129] [Article Influence: 15.3] [Reference Citation Analysis]
55 Gaggini MC, Navarro RS, Stefanini AR, Sano RS, Silveira L Jr. Correlation between METAVIR scores and Raman spectroscopy in liver lesions induced by hepatitis C virus: a preliminary study. Lasers Med Sci 2015;30:1347-55. [PMID: 25794591 DOI: 10.1007/s10103-015-1741-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
56 Batxelli-molina I, Calvayrac-pawlowski S, Moulin V, Lapalus M, Hem S, Laune D, Asselah T, Jardin-watelet B. Novel α-2-macroglobulin cleaved fragments as biomarkers of early liver fibrosis in patients with chronic hepatitis C. Future Virology 2015;10:5-16. [DOI: 10.2217/fvl.14.98] [Reference Citation Analysis]
57 Soresi M, Giannitrapani L, Cervello M, Licata A, Montalto G. Non invasive tools for the diagnosis of liver cirrhosis. World J Gastroenterol 2014; 20(48): 18131-18150 [PMID: 25561782 DOI: 10.3748/wjg.v20.i48.18131] [Cited by in CrossRef: 58] [Cited by in F6Publishing: 63] [Article Influence: 6.4] [Reference Citation Analysis]
58 Gao S, Fan YC, Zhao J, Sun FK, Han J, Zhao ZH, Wang K. A model to predict antiviral treatment in HBeAg negative chronic hepatitis B with alanine aminotransferase≤2 upper limit of normal. Liver Int 2014;34:e229-37. [PMID: 24112455 DOI: 10.1111/liv.12344] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
59 Zeremski M, Dimova RB, Benjamin S, Makeyeva J, Yantiss RK, Gambarin-Gelwan M, Talal AH. FibroSURE as a noninvasive marker of liver fibrosis and inflammation in chronic hepatitis B. BMC Gastroenterol 2014;14:118. [PMID: 24990385 DOI: 10.1186/1471-230X-14-118] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
60 Martyn-simmons C, Rosenberg W, Cross R, Wong T, Smith C, Barker J. Validity of noninvasive markers of methotrexate-induced hepatotoxicity: a retrospective cohort study. Br J Dermatol 2014;171:267-73. [DOI: 10.1111/bjd.12782] [Cited by in Crossref: 20] [Cited by in F6Publishing: 48] [Article Influence: 2.2] [Reference Citation Analysis]
61 Suk KT, Kim DY, Sohn KM, Kim DJ. Biomarkers of liver fibrosis. Adv Clin Chem 2013;62:33-122. [PMID: 24772665 DOI: 10.1016/b978-0-12-800096-0.00002-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
62 Boyraz M, Cekmez F, Karaoglu A, Cinaz P, Durak M, Bideci A. Serum adiponectin, leptin, resistin and RBP4 levels in obese and metabolic syndrome children with nonalcoholic fatty liver disease. Biomark Med. 2013;7:737-745. [PMID: 24044566 DOI: 10.2217/bmm.13.13] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 2.8] [Reference Citation Analysis]
63 Fallatah HI. Noninvasive Biomarkers of Liver Fibrosis: An Overview. Advances in Hepatology 2014;2014:1-15. [DOI: 10.1155/2014/357287] [Cited by in Crossref: 40] [Cited by in F6Publishing: 43] [Article Influence: 4.4] [Reference Citation Analysis]
64 Saludes V, González V, Planas R, Matas L, Ausina V, Martró E. Tools for the diagnosis of hepatitis C virus infection and hepatic fibrosis staging. World J Gastroenterol 2014; 20(13): 3431-3442 [PMID: 24707126 DOI: 10.3748/wjg.v20.i13.3431] [Cited by in CrossRef: 26] [Cited by in F6Publishing: 29] [Article Influence: 2.9] [Reference Citation Analysis]
65 Schiavon LL, Narciso-Schiavon JL, Carvalho-Filho RJ. Non-invasive diagnosis of liver fibrosis in chronic hepatitis C. World J Gastroenterol 2014; 20(11): 2854-2866 [PMID: 24659877 DOI: 10.3748/wjg.v20.i11.2854] [Cited by in CrossRef: 48] [Cited by in F6Publishing: 48] [Article Influence: 5.3] [Reference Citation Analysis]
66 Kang W, Kim SU, Ahn SH. Non-invasive prediction of forthcoming cirrhosis-related complications. World J Gastroenterol 2014; 20(10): 2613-2623 [PMID: 24627597 DOI: 10.3748/wjg.v20.i10.2613] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
67 Ozkurt H, Keskiner F, Karatag O, Alkim C, Erturk SM, Basak M. Diffusion Weighted MRI for Hepatic Fibrosis: Impact of b-Value. Iran J Radiol 2014;11:e3555. [PMID: 24693297 DOI: 10.5812/iranjradiol.3555] [Cited by in Crossref: 4] [Cited by in F6Publishing: 10] [Article Influence: 0.4] [Reference Citation Analysis]
68 Zheng C, Chu YJ, Zhang FB, Li Y, Sun J. Correlation between serum indexes and hepatic biopsy histopathology in patients with autoimmune hepatitis. Shijie Huaren Xiaohua Zazhi 2013; 21(35): 3999-4005 [DOI: 10.11569/wcjd.v21.i35.3999] [Reference Citation Analysis]
69 Martel-Laferrière V, Wong M, Dieterich DT. HIV/hepatitis C virus-coinfected patients and cirrhosis: how to diagnose it and what to do next? Clin Infect Dis 2014;58:840-7. [PMID: 24178247 DOI: 10.1093/cid/cit714] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
70 Cui XW, Friedrich-Rust M, Molo CD, Ignee A, Schreiber-Dietrich D, Dietrich CF. Liver elastography, comments on EFSUMB elastography guidelines 2013. World J Gastroenterol 2013; 19(38): 6329-6347 [PMID: 24151351 DOI: 10.3748/wjg.v19.i38.6329] [Cited by in CrossRef: 32] [Cited by in F6Publishing: 35] [Article Influence: 3.2] [Reference Citation Analysis]
71 Castera L. Natural History of Chronic HCV Infection and Non-Invasive Assessment of Hepatic Fibrosis. Viral Hepatitis 2013. [DOI: 10.1002/9781118637272.ch23] [Reference Citation Analysis]
72 Rath T, Hage L, Kügler M, Menendez Menendez K, Zachoval R, Naehrlich L, Schulz R, Roderfeld M, Roeb E. Serum proteome profiling identifies novel and powerful markers of cystic fibrosis liver disease. PLoS One. 2013;8:e58955. [PMID: 23516586 DOI: 10.1371/journal.pone.0058955] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 2.5] [Reference Citation Analysis]
73 Chen J, Liu C, Chen H, Liu Q, Yang B, Ou Q. Study on noninvasive laboratory tests for fibrosis in chronic HBV infection and their evaluation. J Clin Lab Anal. 2013;27:5-11. [PMID: 23292737 DOI: 10.1002/jcla.21554] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.6] [Reference Citation Analysis]
74 Rossi E, Adams LA, Ching HL, Bulsara M, Macquillan GC, Jeffrey GP. High biological variation of serum hyaluronic acid and Hepascore, a biochemical marker model for the prediction of liver fibrosis. Clinical Chemistry and Laboratory Medicine 2013;51. [DOI: 10.1515/cclm-2012-0584] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
75 Holmes JA, Thompson AJ, Adams LA. Biomarkers of Fibrosis and Fibrosis Progression in Chronic Hepatitis C. Curr Hepatitis Rep 2012;11:231-242. [DOI: 10.1007/s11901-012-0148-0] [Reference Citation Analysis]
76 Fernández-varo G. Marcadores serológicos de fibrosis. Gastroenterología y Hepatología 2012;35:10-6. [DOI: 10.1016/s0210-5705(12)70044-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
77 Oguz A, Atay AE, Tas A, Seven G, Koruk M. Predictive role of acute phase reactants in the response to therapy in patients with chronic hepatitis C virus infection. Gut Liver 2013;7:82-8. [PMID: 23424009 DOI: 10.5009/gnl.2013.7.1.82] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
78 Trifan A, Stanciu C. Checkmate to liver biopsy in chronic hepatitis C? World J Gastroenterol 2012; 18(39): 5514-5520 [PMID: 23112543 DOI: 10.3748/wjg.v18.i39.5514] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
79 Du D, Zhu X, Kuno A, Matsuda A, Tsuruno C, Yu D, Zhang Y, Ikehara Y, Tanaka Y, Zhang X. Comparison of LecT-Hepa and FibroScan for assessment of liver fibrosis in hepatitis B virus infected patients with different ALT levels. Clin Chim Acta. 2012;413:1796-1799. [PMID: 22796373 DOI: 10.1016/j.cca.2012.07.005] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
80 Castera L. Noninvasive methods to assess liver disease in patients with hepatitis B or C. Gastroenterology 2012;142:1293-1302.e4. [PMID: 22537436 DOI: 10.1053/j.gastro.2012.02.017] [Cited by in Crossref: 436] [Cited by in F6Publishing: 463] [Article Influence: 39.6] [Reference Citation Analysis]
81 Paredes AH, Torres DM, Harrison SA. Nonalcoholic fatty liver disease. Clin Liver Dis 2012;16:397-419. [PMID: 22541706 DOI: 10.1016/j.cld.2012.03.005] [Cited by in Crossref: 51] [Cited by in F6Publishing: 56] [Article Influence: 4.6] [Reference Citation Analysis]
82 Mehta SH, Kirk GD, Astemborski J, Sulkowski MS, Afdhal NH, Thomas DL. Stability of liver fibrosis among HCV-infected injection drug users. Antivir Ther 2012;17:813-21. [PMID: 22418880 DOI: 10.3851/IMP2085] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
83 Rockey DC, Friedman SL. Hepatic Fibrosis and Cirrhosis. Zakim and Boyer's Hepatology. Elsevier; 2012. pp. 64-85. [DOI: 10.1016/b978-1-4377-0881-3.00005-x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
84 Sebastiani G, Alberti A. How far is noninvasive assessment of liver fibrosis from replacing liver biopsy in hepatitis C? J Viral Hepat 2012;19 Suppl 1:18-32. [PMID: 22233410 DOI: 10.1111/j.1365-2893.2011.01518.x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 2.8] [Reference Citation Analysis]
85 Park SH, Kim CH, Kim DJ, Suk KT, Park JH, Cheong JY, Cho SW, Hwang SG, Lee YJ, Cho M, Yang JM, Park HY, Kim YB. Diagnostic value of multiple biomarker panel for prediction of significant fibrosis in chronic hepatitis C. Clinical Biochemistry 2011;44:1396-9. [DOI: 10.1016/j.clinbiochem.2011.08.1151] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
86 Osakabe K, Ichino N, Nishikawa T, Sugiyama H, Kato M, Kitahara S, Hashimoto S, Kawabe N, Harata M, Nitta Y, Murao M, Nakano T, Shimazaki H, Arima Y, Suzuki K, Yoshioka K. Reduction of liver stiffness by antiviral therapy in chronic hepatitis B. J Gastroenterol 2011;46:1324-34. [PMID: 21822591 DOI: 10.1007/s00535-011-0444-4] [Cited by in Crossref: 43] [Cited by in F6Publishing: 45] [Article Influence: 3.6] [Reference Citation Analysis]
87 Shah AG, Smith PG, Sterling RK. Comparison of FIB-4 and APRI in HIV-HCV coinfected patients with normal and elevated ALT. Dig Dis Sci 2011;56:3038-44. [PMID: 21526398 DOI: 10.1007/s10620-011-1710-2] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
88 Zhu X, Wang LC, Chen EQ, Chen XB, Chen LY, Liu L, Lei XZ, Liu C, Tang H. Prospective evaluation of FibroScan for the diagnosis of hepatic fibrosis compared with liver biopsy/AST platelet ratio index and FIB-4 in patients with chronic HBV infection. Dig Dis Sci 2011;56:2742-9. [PMID: 21399926 DOI: 10.1007/s10620-011-1659-1] [Cited by in Crossref: 61] [Cited by in F6Publishing: 58] [Article Influence: 5.1] [Reference Citation Analysis]
89 Schmeltzer PA, Talwalkar JA. Noninvasive tools to assess hepatic fibrosis: ready for prime time? Gastroenterol Clin North Am 2011;40:507-21. [PMID: 21893271 DOI: 10.1016/j.gtc.2011.06.010] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 2.8] [Reference Citation Analysis]
90 Baranova A, Lal P, Birerdinc A, Younossi ZM. Non-invasive markers for hepatic fibrosis. BMC Gastroenterol. 2011;11:91. [PMID: 21849046 DOI: 10.1186/1471-230x-11-91] [Cited by in Crossref: 194] [Cited by in F6Publishing: 210] [Article Influence: 16.2] [Reference Citation Analysis]
91 Cheung KJ, Tilleman K, Deforce D, Colle I, Moreno C, Gustot T, Van Vlierberghe H. Usefulness of a novel serum proteome-derived index FI-PRO (fibrosis-protein) in the prediction of fibrosis in chronic hepatitis C. Eur J Gastroenterol Hepatol 2011;23:701-10. [PMID: 21623191 DOI: 10.1097/MEG.0b013e3283471b74] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
92 Shire NJ, Yin M, Chen J, Railkar RA, Fox-Bosetti S, Johnson SM, Beals CR, Dardzinski BJ, Sanderson SO, Talwalkar JA, Ehman RL. Test-retest repeatability of MR elastography for noninvasive liver fibrosis assessment in hepatitis C. J Magn Reson Imaging. 2011;34:947-955. [PMID: 21751289 DOI: 10.1002/jmri.22716] [Cited by in Crossref: 109] [Cited by in F6Publishing: 112] [Article Influence: 9.1] [Reference Citation Analysis]
93 Ismail MH, Pinzani M. Reversal of hepatic fibrosis: pathophysiological basis of antifibrotic therapies. Hepat Med. 2011;3:69-80. [PMID: 24367223 DOI: 10.2147/hmer.s9051] [Cited by in Crossref: 32] [Cited by in F6Publishing: 34] [Article Influence: 2.7] [Reference Citation Analysis]
94 Ismail MH, Pinzani M. Reversal of hepatic fibrosis: pathophysiological basis of antifibrotic therapies. Hepat Med. 2011;3:69-80. [PMID: 24367223 DOI: 10.2147/hmer.s905] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
95 Yan FR, Lin JG, Liu Y. Sparse logistic regression for diagnosis of liver fibrosis in rat by using SCAD-penalized likelihood. J Biomed Biotechnol 2011;2011:875309. [PMID: 21716672 DOI: 10.1155/2011/875309] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
96 Lee HJ, Seo YS, Kim DJ, Kang HS, An H, Kim JH, Cheong JY, Yim HJ, Yeon JE, Lee HS, Byun KS, Cho SW, Kim DJ, Um SH, Kim CD, Ryu HS. Application of the HALF index obviates the need for liver biopsy in half of all patients with chronic hepatitis B. J Gastroenterol Hepatol 2011;26:987-95. [PMID: 21198828 DOI: 10.1111/j.1440-1746.2010.06609.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
97 Galal GM, Amin NF, Abdel Hafeez HA, El-Baz MA. Can serum fibrosis markers predict medium/large oesophageal varices in patients with liver cirrhosis? Arab J Gastroenterol 2011;12:62-7. [PMID: 21684475 DOI: 10.1016/j.ajg.2011.04.003] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
98 Omran MM, Farid K, Emran TM, Attallah AA. Fibro-α score as a simple and useful non-invasive test for predicting significant liver fibrosis in chronic hepatitis C patients. Arab J Gastroenterol. 2011;12:74-79. [PMID: 21684477 DOI: 10.1016/j.ajg.2011.04.006] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.4] [Reference Citation Analysis]
99 Adams LA. Biomarkers of liver fibrosis. J Gastroenterol Hepatol 2011;26:802-9. [PMID: 21198831 DOI: 10.1111/j.1440-1746.2010.06612.x] [Cited by in Crossref: 71] [Cited by in F6Publishing: 69] [Article Influence: 5.9] [Reference Citation Analysis]
100 Castera L. Invasive and non-invasive methods for the assessment of fibrosis and disease progression in chronic liver disease. Best Pract Res Clin Gastroenterol 2011;25:291-303. [PMID: 21497746 DOI: 10.1016/j.bpg.2011.02.003] [Cited by in Crossref: 99] [Cited by in F6Publishing: 103] [Article Influence: 8.3] [Reference Citation Analysis]
101 Macías J, Mira J, Gilabert I, Neukam K, Roldán C, Viloria M, Moro A, Pineda JA. Combined use of aspartate aminotransferase, platelet count and matrix metalloproteinase 2 measurements to predict liver fibrosis in HIV/hepatitis C virus-coinfected patients. HIV Med 2011;12:14-21. [PMID: 20497249 DOI: 10.1111/j.1468-1293.2010.00836.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
102 Ahmad W, Ijaz B, Gull S, Asad S, Khaliq S, Jahan S, Sarwar MT, Kausar H, Sumrin A, Shahid I. A brief review on molecular, genetic and imaging techniques for HCV fibrosis evaluation. Virol J. 2011;8:53. [PMID: 21299910 DOI: 10.1186/1743-422x-8-53] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 2.1] [Reference Citation Analysis]
103 Castera L. Non-invasive assessment of liver fibrosis in chronic hepatitis C. Hepatol Int. 2011;5:625-634. [PMID: 21484142 DOI: 10.1007/s12072-010-9240-0] [Cited by in Crossref: 57] [Cited by in F6Publishing: 64] [Article Influence: 4.8] [Reference Citation Analysis]
104 Khalili H, Dayyeh BA, Friedman LS. Assessment of Liver Function in Clinical Practice. Chronic Liver Failure 2011. [DOI: 10.1007/978-1-60761-866-9_3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
105 Parkes J, Guha IN, Roderick P, Harris S, Cross R, Manos MM, Irving W, Zaitoun A, Wheatley M, Ryder S, Rosenberg W. Enhanced Liver Fibrosis (ELF) test accurately identifies liver fibrosis in patients with chronic hepatitis C. J Viral Hepat 2011;18:23-31. [PMID: 20196799 DOI: 10.1111/j.1365-2893.2009.01263.x] [Cited by in Crossref: 120] [Cited by in F6Publishing: 116] [Article Influence: 10.0] [Reference Citation Analysis]
106 Sebastiani G, Gkouvatsos K, Plebani M. Non-invasive assessment of liver fibrosis: it is time for laboratory medicine. Clin Chem Lab Med. 2011;49:13-32. [PMID: 20961196 DOI: 10.1515/cclm.2011.001] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.3] [Reference Citation Analysis]
107 Lebensztejn DM, Kowalczuk D, Tarasów E, Skiba E, Kaczmarski M. Tumor necrosis factor alpha and its soluble receptors in obese children with NAFLD. Adv Med Sci 2010;55:74-9. [PMID: 20371430 DOI: 10.2478/v10039-010-0008-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
108 Ozer JS, Reagan WJ, Schomaker S, Palandra J, Baratta M, Ramaiah S. Translational Biomarkers of Acute Drug‐Induced Liver Injury: The Current State, Gaps, and Future Opportunities. Biomarkers 2010. [DOI: 10.1002/9780470918562.ch9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
109 Calès P, Boursier J, Bertrais S, Oberti F, Gallois Y, Fouchard-Hubert I, Dib N, Zarski JP, Rousselet MC. Optimization and robustness of blood tests for liver fibrosis and cirrhosis. Clin Biochem. 2010;43:1315-1322. [PMID: 20713037 DOI: 10.1016/j.clinbiochem.2010.08.010] [Cited by in Crossref: 29] [Cited by in F6Publishing: 32] [Article Influence: 2.2] [Reference Citation Analysis]
110 Ho AS, Cheng CC, Lee SC, Liu ML, Lee JY, Wang WM, Wang CC. Novel biomarkers predict liver fibrosis in hepatitis C patients: alpha 2 macroglobulin, vitamin D binding protein and apolipoprotein AI. J Biomed Sci 2010;17:58. [PMID: 20630109 DOI: 10.1186/1423-0127-17-58] [Cited by in Crossref: 63] [Cited by in F6Publishing: 66] [Article Influence: 4.8] [Reference Citation Analysis]
111 Park SH, Kim DJ, Cheong JY, Cho SW, Hwang SG, Lee YJ, Cho M, Yang JM, Kim YB. Noninvasive markers to diagnose cirrhosis in patients with HBeAg positive chronic hepatitis: Do new biomarkers improve the accuracy? Clinical Biochemistry 2010;43:877-81. [DOI: 10.1016/j.clinbiochem.2010.04.063] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
112 Fang M, Zhao YP, Zhou FG, Lu LG, Qi P, Wang H, Zhou K, Sun SH, Chen CY, Gao CF. N-glycan based models improve diagnostic efficacies in hepatitis B virus-related hepatocellular carcinoma. Int J Cancer. 2010;127:148-159. [PMID: 19904744 DOI: 10.1002/ijc.25030] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 2.5] [Reference Citation Analysis]
113 Hu XR, Cui XN, Hu QT, Chen J. Correlation between serum fibrosis markers and the degree of liver fibrosis in patients with chronic hepatitis. Shijie Huaren Xiaohua Zazhi 2010; 18(14): 1501-1503 [DOI: 10.11569/wcjd.v18.i14.1501] [Reference Citation Analysis]
114 Schiavon LL, Carvalho-Filho RJ, Narciso-Schiavon JL, Medina-Pestana JO, Lanzoni VP, Ferraz ML, Silva AE. YKL-40 and hyaluronic acid (HA) as noninvasive markers of liver fibrosis in kidney transplant patients with HCV chronic infection. Scand J Gastroenterol 2010;45:615-22. [PMID: 20163287 DOI: 10.3109/00365521003637203] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
115 Jarcuska P, Janicko M, Veselíny E, Jarcuska P, Skladaný L. Circulating markers of liver fibrosis progression. Clin Chim Acta. 2010;411:1009-1017. [PMID: 20399764 DOI: 10.1016/j.cca.2010.04.009] [Cited by in Crossref: 60] [Cited by in F6Publishing: 70] [Article Influence: 4.6] [Reference Citation Analysis]
116 Bailly F, Ahmed SN, Pradat P, Trepo C. Management of nonresponsive hepatitis C. Expert Rev Anti Infect Ther 2010;8:379-95. [PMID: 20377334 DOI: 10.1586/eri.10.17] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
117 Pinzani M. Non-invasive systems for staging compensated cirrhosis. Arab Journal of Gastroenterology 2010;10:S32-S34. [DOI: 10.1016/j.ajg.2009.12.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
118 Zhang Y, Wang B, Wang T, Ou X. Assessment of hepatic fibrosis by transient elastography in patients with chronic hepatitis B. Pathology International 2010;60:284-90. [DOI: 10.1111/j.1440-1827.2010.02515.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
119 Takahashi H, Ono N, Eguchi Y, Eguchi T, Kitajima Y, Kawaguchi Y, Nakashita S, Ozaki I, Mizuta T, Toda S, Kudo S, Miyoshi A, Miyazaki K, Fujimoto K. Evaluation of acoustic radiation force impulse elastography for fibrosis staging of chronic liver disease: a pilot study. Liver Int 2010;30:538-45. [PMID: 19874490 DOI: 10.1111/j.1478-3231.2009.02130.x] [Cited by in Crossref: 163] [Cited by in F6Publishing: 153] [Article Influence: 12.5] [Reference Citation Analysis]
120 Lebensztejn DM, Wojtkowska M, Skiba E, Werpachowska I, Tobolczyk J, Kaczmarski M. Serum concentration of adiponectin, leptin and resistin in obese children with non-alcoholic fatty liver disease. Adv Med Sci 2009;54:177-82. [PMID: 20022856 DOI: 10.2478/v10039-009-0047-y] [Cited by in Crossref: 28] [Cited by in F6Publishing: 31] [Article Influence: 2.2] [Reference Citation Analysis]
121 Dai CY, Ho CK, Huang JF, Hsieh MY, Hou NJ, Lin ZY, Chen SC, Hsieh MY, Wang LY, Chang WY, Yu ML, Chuang WL. Hepatitis C virus viremia and low platelet count: a study in a hepatitis B & C endemic area in Taiwan. J Hepatol 2010;52:160-6. [PMID: 20034694 DOI: 10.1016/j.jhep.2009.11.017] [Cited by in Crossref: 40] [Cited by in F6Publishing: 41] [Article Influence: 3.1] [Reference Citation Analysis]
122 Ismail MH, Pinzani M. Reversal of liver fibrosis. Saudi J Gastroenterol. 2009;15:72-79. [PMID: 19568569 DOI: 10.4103/1319-3767.45072] [Cited by in Crossref: 70] [Cited by in F6Publishing: 81] [Article Influence: 5.0] [Reference Citation Analysis]
123 Guajardo-Salinas GE, Hilmy A. Prevalence of nonalcoholic fatty liver disease (NAFLD) and utility of FIBROspect II to detect liver fibrosis in morbidly obese Hispano-American patients undergoing gastric bypass. Obes Surg. 2010;20:1647-1653. [PMID: 19957049 DOI: 10.1007/s11695-009-0027-0] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 1.4] [Reference Citation Analysis]
124 Benlloch S, Heredia L, Barquero C, Rayón JM, Pina R, Aguilera V, Prieto M, Berenguer M. Prospective validation of a noninvasive index for predicting liver fibrosis in hepatitis C virus-infected liver transplant recipients. Liver Transpl 2009;15:1798-807. [PMID: 19938146 DOI: 10.1002/lt.21919] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
125 Boursier J, Vergniol J, Sawadogo A, Dakka T, Michalak S, Gallois Y, Le Tallec V, Oberti F, Fouchard-Hubert I, Dib N, Rousselet MC, Konaté A, Amrani N, de Ledinghen V, Calès P. The combination of a blood test and Fibroscan improves the non-invasive diagnosis of liver fibrosis. Liver Int 2009;29:1507-15. [PMID: 19725892 DOI: 10.1111/j.1478-3231.2009.02101.x] [Cited by in Crossref: 91] [Cited by in F6Publishing: 71] [Article Influence: 6.5] [Reference Citation Analysis]
126 Leroy V. Other non-invasive markers of liver fibrosis. Gastroenterol Clin Biol. 2008;32:52-57. [PMID: 18973846 DOI: 10.1016/s0399-8320(08)73993-9] [Cited by in Crossref: 19] [Cited by in F6Publishing: 23] [Article Influence: 1.4] [Reference Citation Analysis]
127 Calès P, Boursier J, Oberti F, Hubert I, Gallois Y, Rousselet MC, Dib N, Moal V, Macchi L, Chevailler A. FibroMeters: a family of blood tests for liver fibrosis. Gastroenterol Clin Biol. 2008;32:40-51. [PMID: 18973845 DOI: 10.1016/s0399-8320(08)73992-7] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 2.5] [Reference Citation Analysis]
128 Ramachandran P, Iredale JP. Reversibility of liver fibrosis. Ann Hepatol 2009;8:283-91. [PMID: 20009126] [Cited by in Crossref: 76] [Cited by in F6Publishing: 72] [Article Influence: 5.4] [Reference Citation Analysis]
129 Smith JO, Sterling RK. Systematic review: non-invasive methods of fibrosis analysis in chronic hepatitis C. Aliment Pharmacol Ther 2009;30:557-76. [PMID: 19519733 DOI: 10.1111/j.1365-2036.2009.04062.x] [Cited by in Crossref: 87] [Cited by in F6Publishing: 74] [Article Influence: 6.2] [Reference Citation Analysis]
130 Pissaia A Jr, Borderie D, Bernard D, Scatton O, Calmus Y, Conti F. APRI and FIB-4 Scores Are Useful After Liver Transplantation Independently of Etiology. Transplant Proc. 2009;41:679-681. [PMID: 19328955 DOI: 10.1016/j.transproceed.2008.12.014] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 1.5] [Reference Citation Analysis]
131 Miele L, Forgione A, La Torre G, Vero V, Cefalo C, Racco S, Vellone VG, Vecchio FM, Gasbarrini G, Rapaccini GL, Neuman MG, Grieco A. Serum levels of hyaluronic acid and tissue metalloproteinase inhibitor-1 combined with age predict the presence of nonalcoholic steatohepatitis in a pilot cohort of subjects with nonalcoholic fatty liver disease. Transl Res. 2009;154:194-201. [PMID: 19766963 DOI: 10.1016/j.trsl.2009.06.007] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 2.1] [Reference Citation Analysis]
132 Cross TJ, Rizzi P, Berry PA, Bruce M, Portmann B, Harrison PM. King's Score: an accurate marker of cirrhosis in chronic hepatitis C. Eur J Gastroenterol Hepatol 2009;21:730-8. [PMID: 19430302 DOI: 10.1097/MEG.0b013e32830dfcb3] [Cited by in Crossref: 91] [Cited by in F6Publishing: 83] [Article Influence: 6.5] [Reference Citation Analysis]
133 Nitta Y, Kawabe N, Hashimoto S, Harata M, Komura N, Kobayashi K, Arima Y, Shimazaki H, Nakano T, Murao M, Ichino N, Osakabe K, Aoki H, Hosoe Y, Sugiyama H, Nishikawa T, Yoshioka K. Liver stiffness measured by transient elastography correlates with fibrosis area in liver biopsy in patients with chronic hepatitis C. Hepatol Res 2009;39:675-84. [PMID: 19261000 DOI: 10.1111/j.1872-034X.2009.00500.x] [Cited by in Crossref: 65] [Cited by in F6Publishing: 69] [Article Influence: 4.6] [Reference Citation Analysis]
134 Cheung KJ, Tilleman K, Deforce D, Colle I, Van Vlierberghe H. The HCV serum proteome: a search for fibrosis protein markers. J Viral Hepat 2009;16:418-29. [PMID: 19226329 DOI: 10.1111/j.1365-2893.2009.01083.x] [Cited by in Crossref: 61] [Cited by in F6Publishing: 54] [Article Influence: 4.4] [Reference Citation Analysis]
135 Lee JH, Yoon JH, Lee CH, Myung SJ, Keam B, Kim BH, Chung GE, Kim W, Kim YJ, Jang JJ, Lee HS. Complete blood count reflects the degree of oesophageal varices and liver fibrosis in virus-related chronic liver disease patients. J Viral Hepat 2009;16:444-52. [PMID: 19200133 DOI: 10.1111/j.1365-2893.2009.01091.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
136 Sebastiani G. Non-invasive assessment of liver fibrosis in chronic liver diseases: Implementation in clinical practice and decisional algorithms. World J Gastroenterol 2009; 15(18): 2190-2203 [PMID: 19437558 DOI: 10.3748/wjg.15.2190] [Cited by in CrossRef: 54] [Cited by in F6Publishing: 60] [Article Influence: 3.9] [Reference Citation Analysis]
137 Castera L. Transient elastography and other noninvasive tests to assess hepatic fibrosis in patients with viral hepatitis. J Viral Hepat 2009;16:300-14. [PMID: 19254351 DOI: 10.1111/j.1365-2893.2009.01087.x] [Cited by in Crossref: 119] [Cited by in F6Publishing: 108] [Article Influence: 8.5] [Reference Citation Analysis]
138 Takemoto R, Nakamuta M, Aoyagi Y, Fujino T, Yasutake K, Koga K, Yoshimoto T, Miyahara T, Fukuizumi K, Wada Y, Takami Y, Saitsu H, Harada N, Nakashima M, Enjoji M. Validity of FibroScan values for predicting hepatic fibrosis stage in patients with chronic HCV infection. J Dig Dis 2009;10:145-8. [PMID: 19426398 DOI: 10.1111/j.1751-2980.2009.00377.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 1.4] [Reference Citation Analysis]
139 Carlson JJ, Kowdley KV, Sullivan SD, Ramsey SD, Veenstra DL. An evaluation of the potential cost-effectiveness of non-invasive testing strategies in the diagnosis of significant liver fibrosis. J Gastroenterol Hepatol 2009;24:786-91. [PMID: 19457153 DOI: 10.1111/j.1440-1746.2009.05778.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 1.6] [Reference Citation Analysis]
140 Shire NJ, Rao MB, Succop P, Buncher CR, Andersen JA, Butt AA, Chung RT, Sherman KE; AIDS Clinical Trials Group 5178 Study Group. Improving noninvasive methods of assessing liver fibrosis in patients with hepatitis C virus/human immunodeficiency virus co-infection. Clin Gastroenterol Hepatol 2009;7:471-80, 480.e1-2. [PMID: 19268724 DOI: 10.1016/j.cgh.2008.12.016] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 0.8] [Reference Citation Analysis]
141 Moreno S, García-Samaniego J, Moreno A, Ortega E, Pineda JA, del Romero J, Tural C, von Wichmann MA, Berenguer J, Castro A, Espacio R. Noninvasive diagnosis of liver fibrosis in patients with HIV infection and HCV/HBV co-infection. J Viral Hepat 2009;16:249-58. [PMID: 19215579 DOI: 10.1111/j.1365-2893.2009.01088.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 1.5] [Reference Citation Analysis]
142 Vergniol J, de Ledinghen V. Diagnostic non invasif de la fibrose hépatique : modalités pratiques d’utilisation des marqueurs sanguins et du FibroScan. Gastroentérologie Clinique et Biologique 2009;33:334-44. [DOI: 10.1016/j.gcb.2009.02.014] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
143 Castera L. Assessing liver fibrosis. Expert Rev Gastroenterol Hepatol. 2008;2:541-552. [PMID: 19072402 DOI: 10.1586/17474124.2.4.541] [Cited by in Crossref: 27] [Cited by in F6Publishing: 30] [Article Influence: 1.9] [Reference Citation Analysis]
144 Patel K, Benhamou Y, Yoshida EM, Kaita KD, Zeuzem S, Torbenson M, Pulkstenis E, Subramanian GM, McHutchison JG. An independent and prospective comparison of two commercial fibrosis marker panels (HCV FibroSURE and FIBROSpect II) during albinterferon alfa-2b combination therapy for chronic hepatitis C. J Viral Hepat 2009;16:178-86. [PMID: 19175870 DOI: 10.1111/j.1365-2893.2008.01062.x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 2.1] [Reference Citation Analysis]
145 Tural C, Tor J, Sanvisens A, Pérez-Alvarez N, Martínez E, Ojanguren I, García-Samaniego J, Rockstroh J, Barluenga E, Muga R, Planas R, Sirera G, Rey-Joly C, Clotet B. Accuracy of simple biochemical tests in identifying liver fibrosis in patients co-infected with human immunodeficiency virus and hepatitis C virus. Clin Gastroenterol Hepatol 2009;7:339-45. [PMID: 19171202 DOI: 10.1016/j.cgh.2008.11.019] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 2.1] [Reference Citation Analysis]
146 Corradi F, Piscaglia F, Flori S, D'Errico-Grigioni A, Vasuri F, Tamé MR, Andreone P, Boni P, Gianstefani A, Bolondi L; Bologna Liver Transplantation Group. Assessment of liver fibrosis in transplant recipients with recurrent HCV infection: usefulness of transient elastography. Dig Liver Dis 2009;41:217-25. [PMID: 18672413 DOI: 10.1016/j.dld.2008.06.009] [Cited by in Crossref: 60] [Cited by in F6Publishing: 60] [Article Influence: 4.3] [Reference Citation Analysis]
147 Carpentier A, Conti F, Carrière M, Aoudjehane L, Miroux C, Moralès O, Calmus Y, Groux H, Auriault C, Pancré V, Delhem N, Podevin P. Analysis of gene transcription in sera during chronic hepatitis C infection. J Med Virol 2009;81:473-80. [PMID: 19152403 DOI: 10.1002/jmv.21398] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
148 Zhou K, Lu LG. Assessment of fibrosis in chronic liver diseases. J Dig Dis 2009;10:7-14. [PMID: 19236541 DOI: 10.1111/j.1751-2980.2008.00356.x] [Cited by in Crossref: 38] [Cited by in F6Publishing: 41] [Article Influence: 2.7] [Reference Citation Analysis]
149 Mehta SH, Lau B, Afdhal NH, Thomas DL. Exceeding the limits of liver histology markers. J Hepatol 2009;50:36-41. [PMID: 19012989 DOI: 10.1016/j.jhep.2008.07.039] [Cited by in Crossref: 199] [Cited by in F6Publishing: 200] [Article Influence: 14.2] [Reference Citation Analysis]
150 Kim SG, Kim YS, Jung SW, Kim HK, Jang JY, Moon JH, Kim HS, Lee JS, Lee MS, Shim CS, Kim BS. The usefulness of transient elastography to diagnose cirrhosis in patients with alcoholic liver disease. Korean J Hepatol 2009;15:42. [DOI: 10.3350/kjhep.2009.15.1.42] [Cited by in Crossref: 26] [Cited by in F6Publishing: 30] [Article Influence: 1.9] [Reference Citation Analysis]
151 Dioguardi N, Grizzi F, Fiamengo B, Russo C. Metrically measuring liver biopsy: A chronic hepatitis B and C computer-aided morphologic description. World J Gastroenterol 2008; 14(48): 7335-7344 [PMID: 19109867 DOI: 10.3748/wjg.14.7335] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 13] [Article Influence: 0.7] [Reference Citation Analysis]
152 Shiha G, Sarin SK, Ibrahim AE, Omata M, Kumar A, Lesmana LA, Leung N, Tozun N, Hamid S, Jafri W, Maruyama H, Bedossa P, Pinzani M, Chawla Y, Esmat G, Doss W, Elzanaty T, Sakhuja P, Nasr AM, Omar A, Wai CT, Abdallah A, Salama M, Hamed A, Yousry A, Waked I, Elsahar M, Fateen A, Mogawer S, Hamdy H, Elwakil R, Jury of the APASL Consensus Development Meeting 29 January 2008 on Liver Fibrosis With Without Hepatitis B or C. Liver fibrosis: consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL). Hepatol Int. 2009;3:323-333. [PMID: 19669358 DOI: 10.1007/s12072-008-9114-x] [Cited by in Crossref: 66] [Cited by in F6Publishing: 75] [Article Influence: 4.4] [Reference Citation Analysis]
153 Srygley FD, Patel K. Noninvasive assessment of liver fibrosis in chronic hepatitis C infection. Curr hepatitis rep 2008;7:164-172. [DOI: 10.1007/s11901-008-0032-0] [Reference Citation Analysis]
154 Paggi S, Colli A, Fraquelli M, Viganò M, Del Poggio P, Facciotto C, Colombo M, Ronchi G, Conte D. A non-invasive algorithm accurately predicts advanced fibrosis in hepatitis C: a comparison using histology with internal-external validation. J Hepatol 2008;49:564-71. [PMID: 18706734 DOI: 10.1016/j.jhep.2008.07.007] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 1.5] [Reference Citation Analysis]
155 Fontanges T, Bailly F, Trepo E, Chevallier M, Maynard-muet M, Nalet B, Beorchia S, Pillon D, Moindrot H, Froissart B, Slaoui M, Tinel X, Pradat P, Trepo C. Discordance between biochemical markers of liver activity and fibrosis (Actitest®–Fibrotest®) and liver biopsy in patients with chronic hepatitis C. Gastroentérologie Clinique et Biologique 2008;32:858-65. [DOI: 10.1016/j.gcb.2008.05.019] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
156 Das SK, Vasudevan DM. Genesis of hepatic fibrosis and its biochemical markers. Scand J Clin Lab Invest. 2008;68:260-269. [PMID: 18609066 DOI: 10.1080/00365510701668516] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 1.6] [Reference Citation Analysis]
157 Pinzani M, Vizzutti F. Clinical evaluation of disease progression in chronic liver disease: towards an integrated system? Liver Cirrhosis: From Pathophysiology to Disease Management. [DOI: 10.1007/978-1-4020-8656-4_15] [Reference Citation Analysis]
158 Schiavon LL, Narciso-Schiavon JL, Carvalho Filho RJ, Sampaio JP, Medina-Pestana JO, Lanzoni VP, Silva AE, Ferraz ML. Serum levels of YKL-40 and hyaluronic acid as noninvasive markers of liver fibrosis in haemodialysis patients with chronic hepatitis C virus infection. J Viral Hepat 2008;15:666-74. [PMID: 18482283 DOI: 10.1111/j.1365-2893.2008.00992.x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 2.0] [Reference Citation Analysis]
159 Kotlyar DS, Blonski W, Rustgi VK. Noninvasive monitoring of hepatitis C fibrosis progression. Clin Liver Dis 2008;12:557-71, viii. [PMID: 18625428 DOI: 10.1016/j.cld.2008.03.006] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
160 Cross T, Antoniades C, Harrison P. Non-invasive markers for the prediction of fibrosis in chronic hepatitis C infection. Hepatol Res 2008;38:762-9. [PMID: 18462378 DOI: 10.1111/j.1872-034X.2008.00364.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 0.5] [Reference Citation Analysis]
161 Yoshioka K, Kawabe N, Hashimoto S. Transient elastography: Applications and limitations. Hepatol Res 2008;38:1063-8. [PMID: 18624715 DOI: 10.1111/j.1872-034X.2008.00386.x] [Cited by in Crossref: 46] [Cited by in F6Publishing: 44] [Article Influence: 3.1] [Reference Citation Analysis]
162 Camacho VR, Silveira TR, Oliveira JR, Barros SG, Cerski CT. Relationship between serum concetrations of type III procollagen, hyluronic acid and histopathological findings in the liver of HCV-positive blood donors. Arq Gastroenterol 2007;44:118-22. [PMID: 17962855 DOI: 10.1590/s0004-28032007000200006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
163 Guéchot J, Edrief S, Lasnier E, Küper R. Automated assay of hyaluronic acid in serum. Immuno-analyse & Biologie Spécialisée 2008;23:148-52. [DOI: 10.1016/j.immbio.2008.02.011] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
164 Aita JS, Harrison SA. Liver biopsy versus noninvasive testing in chronic hepatitis C: Where do we stand in 2008? Curr hepatitis rep 2008;7:51-9. [DOI: 10.1007/s11901-008-0008-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
165 Manning DS, Afdhal NH. Diagnosis and quantitation of fibrosis. Gastroenterology 2008;134:1670-81. [PMID: 18471546 DOI: 10.1053/j.gastro.2008.03.001] [Cited by in Crossref: 298] [Cited by in F6Publishing: 320] [Article Influence: 19.9] [Reference Citation Analysis]
166 Wallace K, Burt AD, Wright MC. Liver fibrosis. Biochem J. 2008;411:1-18. [PMID: 18333835 DOI: 10.1042/bj20071570] [Cited by in Crossref: 227] [Cited by in F6Publishing: 250] [Article Influence: 15.1] [Reference Citation Analysis]
167 Mehta P, Ploutz-Snyder R, Nandi J, Rawlins SR, Sanderson SO, Levine RA. Diagnostic accuracy of serum hyaluronic acid, FIBROSpect II, and YKL-40 for discriminating fibrosis stages in chronic hepatitis C. Am J Gastroenterol 2008;103:928-36. [PMID: 18371145 DOI: 10.1111/j.1572-0241.2007.01761.x] [Cited by in Crossref: 64] [Cited by in F6Publishing: 61] [Article Influence: 4.3] [Reference Citation Analysis]
168 Schuppan D, Afdhal NH. Liver cirrhosis. Lancet. 2008;371:838-851. [PMID: 18328931 DOI: 10.1056/s0140-6736(08)60383-9] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
169 Schuppan D, Afdhal NH. Liver cirrhosis. Lancet. 2008;371:838-851. [PMID: 18328931 DOI: 10.1016/s0140-6736(08)60383-9] [Cited by in Crossref: 1387] [Cited by in F6Publishing: 1184] [Article Influence: 92.5] [Reference Citation Analysis]
170 Romero-Gómez M, Gómez-González E, Madrazo A, Vera-Valencia M, Rodrigo L, Pérez-Alvarez R, Pérez-López R, Castellano-Megias VM, Nevado-Santos M, Alcón JC, Solá R, Pérez-Moreno JM, Navarro JM, Andrade RJ, Salmerón J, Fernández-López M, Aznar R, Diago M. Optical analysis of computed tomography images of the liver predicts fibrosis stage and distribution in chronic hepatitis C. Hepatology 2008;47:810-6. [PMID: 18098299 DOI: 10.1002/hep.22112] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 2.4] [Reference Citation Analysis]
171 Patel K, Nelson DR, Rockey DC, Afdhal NH, Smith KM, Oh E, Hettinger K, Vallée M, Dev A, Smith-Riggs M, McHutchison JG. Correlation of FIBROSpect II with histologic and morphometric evaluation of liver fibrosis in chronic hepatitis C. Clin Gastroenterol Hepatol 2008;6:242-7. [PMID: 18187364 DOI: 10.1016/j.cgh.2007.11.009] [Cited by in Crossref: 43] [Cited by in F6Publishing: 45] [Article Influence: 2.9] [Reference Citation Analysis]
172 Pinzani M, Vizzutti F, Arena U, Marra F. Technology Insight: noninvasive assessment of liver fibrosis by biochemical scores and elastography. Nat Rev Gastroenterol Hepatol 2008;5:95-106. [DOI: 10.1038/ncpgasthep1025] [Cited by in Crossref: 125] [Cited by in F6Publishing: 141] [Article Influence: 8.3] [Reference Citation Analysis]
173 Gressner OA, Weiskirchen R, Gressner AM. Biomarkers of hepatic fibrosis, fibrogenesis and genetic pre-disposition pending between fiction and reality. J Cell Mol Med. 2007;11:1031-1051. [PMID: 17979881 DOI: 10.1111/j.1582-4934.2007.00092.x] [Cited by in Crossref: 72] [Cited by in F6Publishing: 76] [Article Influence: 4.8] [Reference Citation Analysis]
174 Harrison SA. Is the FIBROSpect II® index effective for determining the stage of fibrosis in patients with chronic hepatitis C? Nat Rev Gastroenterol Hepatol 2008;5:138-9. [DOI: 10.1038/ncpgasthep1035] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
175 Ogawa E, Furusyo N, Toyoda K, Takeoka H, Otaguro S, Hamada M, Murata M, Sawayama Y, Hayashi J. Transient elastography for patients with chronic hepatitis B and C virus infection: Non-invasive, quantitative assessment of liver fibrosis. Hepatol Res 2007;37:1002-10. [PMID: 17608672 DOI: 10.1111/j.1872-034X.2007.00160.x] [Cited by in Crossref: 68] [Cited by in F6Publishing: 71] [Article Influence: 4.3] [Reference Citation Analysis]
176 Berenguer J, Bellón JM, Miralles P, Alvarez E, Sánchez-Conde M, Cosín J, López JC, Alvarez F, Catalán P, Resino S. Identification of liver fibrosis in HIV/HCV-coinfected patients using a simple predictive model based on routine laboratory data. J Viral Hepat 2007;14:859-69. [PMID: 18070289 DOI: 10.1111/j.1365-2893.2007.00881.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 0.1] [Reference Citation Analysis]
177 Shaheen AA, Wan AF, Myers RP. FibroTest and FibroScan for the prediction of hepatitis C-related fibrosis: a systematic review of diagnostic test accuracy. Am J Gastroenterol 2007;102:2589-600. [PMID: 17850410 DOI: 10.1111/j.1572-0241.2007.01466.x] [Cited by in Crossref: 250] [Cited by in F6Publishing: 259] [Article Influence: 15.6] [Reference Citation Analysis]
178 Morra R, Munteanu M, Imbert-Bismut F, Messous D, Ratziu V, Poynard T. FibroMAX: towards a new universal biomarker of liver disease? Expert Rev Mol Diagn 2007;7:481-90. [PMID: 17892356 DOI: 10.1586/14737159.7.5.481] [Cited by in Crossref: 37] [Cited by in F6Publishing: 43] [Article Influence: 2.3] [Reference Citation Analysis]
179 Zarski J, Bedossa P, Bronowicki J, Doffoel M, Poynard T. Utilisation des marqueurs non invasifs de fibrose dans la prise en charge de l’hépatite C. Gastroentérologie Clinique et Biologique 2007;31:34-9. [DOI: 10.1016/s0399-8320(07)92561-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
180 Shaheen AA, Myers RP. Diagnostic accuracy of the aspartate aminotransferase-to-platelet ratio index for the prediction of hepatitis C-related fibrosis: a systematic review. Hepatology 2007;46:912-21. [PMID: 17705266 DOI: 10.1002/hep.21835] [Cited by in Crossref: 268] [Cited by in F6Publishing: 226] [Article Influence: 16.8] [Reference Citation Analysis]
181 Lewin M, Poujol-Robert A, Boëlle PY, Wendum D, Lasnier E, Viallon M, Guéchot J, Hoeffel C, Arrivé L, Tubiana JM, Poupon R. Diffusion-weighted magnetic resonance imaging for the assessment of fibrosis in chronic hepatitis C. Hepatology 2007;46:658-65. [PMID: 17663420 DOI: 10.1002/hep.21747] [Cited by in Crossref: 205] [Cited by in F6Publishing: 206] [Article Influence: 12.8] [Reference Citation Analysis]
182 Stauber RE, Lackner C. Noninvasive diagnosis of hepatic fibrosis in chronic hepatitis C. World J Gastroenterol 2007; 13(32): 4287-4294 [PMID: 17708599 DOI: 10.3748/wjg.v13.i32.4287] [Cited by in CrossRef: 35] [Cited by in F6Publishing: 36] [Article Influence: 2.2] [Reference Citation Analysis]
183 Palacios Pérez Á, Salmerón Escobar J. Papel de la biopsia hepática en el diagnóstico y el control de la hepatitis C crónica. Gastroenterología y Hepatología 2007;30:402-7. [DOI: 10.1157/13108806] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
184 White IR, Patel K, Symonds WT, Dev A, Griffin P, Tsokanas N, Skehel M, Liu C, Zekry A, Cutler P. Serum proteomic analysis focused on fibrosis in patients with hepatitis C virus infection. J Transl Med. 2007;5:33. [PMID: 17625010 DOI: 10.1186/1479-5876-5-33] [Cited by in Crossref: 35] [Cited by in F6Publishing: 43] [Article Influence: 2.2] [Reference Citation Analysis]
185 Watanabe N, Ikeda H, Nakamura K, Ohkawa R, Kume Y, Aoki J, Hama K, Okudaira S, Tanaka M, Tomiya T, Yanase M, Tejima K, Nishikawa T, Arai M, Arai H, Omata M, Fujiwara K, Yatomi Y. Both plasma lysophosphatidic acid and serum autotaxin levels are increased in chronic hepatitis C. J Clin Gastroenterol 2007;41:616-23. [PMID: 17577119 DOI: 10.1097/01.mcg.0000225642.90898.0e] [Cited by in Crossref: 143] [Cited by in F6Publishing: 146] [Article Influence: 8.9] [Reference Citation Analysis]
186 Soriano V, Puoti M, Sulkowski M, Cargnel A, Benhamou Y, Peters M, Mauss S, Bräu N, Hatzakis A, Pol S, Rockstroh J. Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel. AIDS 2007;21:1073-89. [PMID: 17502718 DOI: 10.1097/QAD.0b013e3281084e4d] [Cited by in Crossref: 258] [Cited by in F6Publishing: 265] [Article Influence: 16.1] [Reference Citation Analysis]
187 Zhao L, Li T, Wang Y, Pan Y, Ning H, Hui X, Xie H, Wang J, Han Y, Liu Z. Elevated plasma osteopontin level is predictive of cirrhosis in patients with hepatitis B infection. Int J Clin Pract. 2008;62:1056-1062. [PMID: 17537188 DOI: 10.1111/j.1742-1241.2007.01368.x] [Cited by in Crossref: 50] [Cited by in F6Publishing: 57] [Article Influence: 3.1] [Reference Citation Analysis]
188 Attallah AM, Mosa TE, Omran MM, Abo-Zeid MM, El-Dosoky I, Shaker YM. Immunodetection of collagen types I, II, III, and IV for differentiation of liver fibrosis stages in patients with chronic HCV. J Immunoassay Immunochem 2007;28:155-68. [PMID: 17424834 DOI: 10.1080/15321810701212088] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 1.7] [Reference Citation Analysis]
189 Lim JK, Groszmann RJ. Transient elastography for diagnosis of portal hypertension in liver cirrhosis: is there still a role for hepatic venous pressure gradient measurement? Hepatology 2007;45:1087-90. [PMID: 17464984 DOI: 10.1002/hep.21731] [Cited by in Crossref: 52] [Cited by in F6Publishing: 44] [Article Influence: 3.3] [Reference Citation Analysis]
190 Burroughs AK, Cholongitas E. Non-invasive tests for liver fibrosis: encouraging or discouraging results? J Hepatol 2007;46:751-5. [PMID: 17383047 DOI: 10.1016/j.jhep.2007.02.017] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 1.4] [Reference Citation Analysis]
191 Leroy V, Hilleret MN, Sturm N, Trocme C, Renversez JC, Faure P, Morel F, Zarski JP. Prospective comparison of six non-invasive scores for the diagnosis of liver fibrosis in chronic hepatitis C. J Hepatol 2007;46:775-82. [PMID: 17321634 DOI: 10.1016/j.jhep.2006.12.013] [Cited by in Crossref: 172] [Cited by in F6Publishing: 172] [Article Influence: 10.8] [Reference Citation Analysis]
192 Boursier J, Dib N, Oberti F, Calès P. Caractéristiques et interprétation des tests sanguins de fibrose hépatique. Gastroentérologie Clinique et Biologique 2007;31:511-23. [DOI: 10.1016/s0399-8320(07)89421-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
193 Esmat G, Metwally M, Zalata KR, Gadalla S, Abdel-Hamid M, Abouzied A, Shaheen AA, El-Raziky M, Khatab H, El-Kafrawy S, Mikhail N, Magder LS, Afdhal NH, Strickland GT. Evaluation of serum biomarkers of fibrosis and injury in Egyptian patients with chronic hepatitis C. J Hepatol 2007;46:620-7. [PMID: 17316875 DOI: 10.1016/j.jhep.2006.12.010] [Cited by in Crossref: 34] [Cited by in F6Publishing: 37] [Article Influence: 2.1] [Reference Citation Analysis]
194 Afdhal NH, Curry M. Technology evaluation: a critical step in the clinical utilization of novel diagnostic tests for liver fibrosis. J Hepatol 2007;46:543-5. [PMID: 17316879 DOI: 10.1016/j.jhep.2007.01.008] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 2.1] [Reference Citation Analysis]
195 Zaman A, Rosen HR, Ingram K, Corless CL, Oh E, Smith K. Assessment of FIBROSpect II to detect hepatic fibrosis in chronic hepatitis C patients. Am J Med. 2007;120:280.e9-280.14. [PMID: 17349453 DOI: 10.1016/j.amjmed.2006.06.044] [Cited by in Crossref: 42] [Cited by in F6Publishing: 48] [Article Influence: 2.6] [Reference Citation Analysis]
196 Snyder N, Nguyen A, Gajula L, Soloway R, Xiao SY, Lau DT, Petersen J. The APRI may be enhanced by the use of the FIBROSpect II in the estimation of fibrosis in chronic hepatitis C. Clin Chim Acta. 2007;381:119-123. [PMID: 17442291 DOI: 10.1016/j.cca.2007.02.046] [Cited by in Crossref: 28] [Cited by in F6Publishing: 31] [Article Influence: 1.8] [Reference Citation Analysis]
197 Terrault NA, Adey DB. The kidney transplant recipient with hepatitis C infection: pre- and posttransplantation treatment. Clin J Am Soc Nephrol. 2007;2:563-575. [PMID: 17699464 DOI: 10.2215/cjn.02930806] [Cited by in Crossref: 57] [Cited by in F6Publishing: 59] [Article Influence: 3.6] [Reference Citation Analysis]
198 Sterling RK, Lyons CD, Stravitz RT, Luketic VA, Sanyal AJ, Carr ME, Smith TJ, Hackney MH, Contos MJ, Mills SA, Kuhn JG, Nolte ME, Shiffman ML. Percutaneous liver biopsy in adult haemophiliacs with hepatitis C virus: safety of outpatient procedure and impact of human immunodeficiency virus coinfection on the spectrum of liver disease. Haemophilia 2007;13:164-71. [DOI: 10.1111/j.1365-2516.2006.01322.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
199 Halfon P, Bacq Y, De Muret A, Penaranda G, Bourliere M, Ouzan D, Tran A, Botta D, Renou C, Bréchot MC, Degott C, Paradis V. Comparison of test performance profile for blood tests of liver fibrosis in chronic hepatitis C. J Hepatol 2007;46:395-402. [PMID: 17156890 DOI: 10.1016/j.jhep.2006.09.020] [Cited by in Crossref: 98] [Cited by in F6Publishing: 99] [Article Influence: 6.1] [Reference Citation Analysis]
200 Halfon P, Bourlière M, Pénaranda G, Cacoub P. Intérêt et limites des méthodes non invasives de prédiction de la fibrose hépatique au cours de l'hépatite C: une alternative à la biopsie hépatique. La Presse Médicale 2007;36:457-66. [DOI: 10.1016/j.lpm.2007.01.007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
201 Gressner OA, Weiskirchen R, Gressner AM. Biomarkers of liver fibrosis: clinical translation of molecular pathogenesis or based on liver-dependent malfunction tests. Clin Chim Acta. 2007;381:107-113. [PMID: 17399697 DOI: 10.1016/j.cca.2007.02.038] [Cited by in Crossref: 136] [Cited by in F6Publishing: 149] [Article Influence: 8.5] [Reference Citation Analysis]
202 Mooney P, Hayes P, Smith K. The putative use of alpha-1-acid glycoprotein as a non-invasive marker of fibrosis. Biomed Chromatogr 2006;20:1351-8. [PMID: 17004233 DOI: 10.1002/bmc.704] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
203 Nguyen-khac E. Résultats et place du Fibroscan® dans le diagnostic non invasif de la fibrose hépatique. La Revue de Médecine Interne 2007;28:94-102. [DOI: 10.1016/j.revmed.2006.10.329] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
204 Koda M, Matunaga Y, Kawakami M, Kishimoto Y, Suou T, Murawaki Y. FibroIndex, a practical index for predicting significant fibrosis in patients with chronic hepatitis C. Hepatology 2007;45:297-306. [PMID: 17256741 DOI: 10.1002/hep.21520] [Cited by in Crossref: 175] [Cited by in F6Publishing: 158] [Article Influence: 10.9] [Reference Citation Analysis]
205 de Franchis R, Dell'Era A. Non-invasive diagnosis of cirrhosis and the natural history of its complications. Best Pract Res Clin Gastroenterol 2007;21:3-18. [PMID: 17223493 DOI: 10.1016/j.bpg.2006.07.001] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 1.8] [Reference Citation Analysis]
206 Grizzi F, Russo C, Franceschini B, Rocco MD, Torri V, Morenghi E, Fassati LR, Dioguardi N. Sampling variability of computer-aided fractal-corrected measures of liver fibrosis in needle biopsy specimens. World J Gastroenterol 2006; 12(47): 7660-7665 [PMID: 17171796 DOI: 10.3748/wjg.v12.i47.7660] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
207 Carrión JA, Navasa M, Bosch J, Bruguera M, Gilabert R, Forns X. Transient elastography for diagnosis of advanced fibrosis and portal hypertension in patients with hepatitis C recurrence after liver transplantation. Liver Transpl 2006;12:1791-8. [PMID: 16823833 DOI: 10.1002/lt.20857] [Cited by in Crossref: 314] [Cited by in F6Publishing: 320] [Article Influence: 18.5] [Reference Citation Analysis]
208 Calmus Y, Conti F, Vaubourdolle M. Le suivi biologique avant et après transplantation hépatique. Revue Francophone des Laboratoires 2006;2006:79-86. [DOI: 10.1016/s1773-035x(06)80502-2] [Reference Citation Analysis]
209 Nguyen-Khac E, Capron D. Noninvasive diagnosis of liver fibrosis by ultrasonic transient elastography (Fibroscan). Eur J Gastroenterol Hepatol 2006;18:1321-5. [PMID: 17099382 DOI: 10.1097/01.meg.0000243884.55562.37] [Cited by in Crossref: 51] [Cited by in F6Publishing: 49] [Article Influence: 3.0] [Reference Citation Analysis]
210 Parise ER, Oliveira AC, Figueiredo-Mendes C, Lanzoni V, Martins J, Nader H, Ferraz ML. Noninvasive serum markers in the diagnosis of structural liver damage in chronic hepatitis C virus infection. Liver Int 2006;26:1095-9. [PMID: 17032410 DOI: 10.1111/j.1478-3231.2006.01356.x] [Cited by in Crossref: 44] [Cited by in F6Publishing: 46] [Article Influence: 2.6] [Reference Citation Analysis]
211 Albanis E, Friedman SL. Diagnosis of hepatic fibrosis in patients with chronic hepatitis C. Clin Liver Dis 2006;10:821-33. [PMID: 17164119 DOI: 10.1016/j.cld.2006.08.027] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
212 Guéchot J. [Noninvasive assessment of liver fibrosis in patients with chronic hepatitis virus C]. Presse Med. 2006;35:1317-1326. [PMID: 16969327 DOI: 10.1016/s0755-4982(06)74811-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
213 Christensen C, Bruden D, Livingston S, Deubner H, Homan C, Smith K, Oh E, Gretch D, Williams J, McMahon B. Diagnostic accuracy of a fibrosis serum panel (FIBROSpect II) compared with Knodell and Ishak liver biopsy scores in chronic hepatitis C patients. J Viral Hepat 2006;13:652-8. [PMID: 16970596 DOI: 10.1111/j.1365-2893.2006.00743.x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 1.8] [Reference Citation Analysis]
214 Fontana RJ, Kleiner DE, Bilonick R, Terrault N, Afdhal N, Belle SH, Jeffers LJ, Ramcharran D, Ghany MG, Hoofnagle JH; Virahep-C Study Group. Modeling hepatic fibrosis in African American and Caucasian American patients with chronic hepatitis C virus infection. Hepatology 2006;44:925-35. [PMID: 17006909 DOI: 10.1002/hep.21335] [Cited by in Crossref: 47] [Cited by in F6Publishing: 29] [Article Influence: 2.8] [Reference Citation Analysis]
215 Comar KM, Sterling RK. Coinfection with hepatitis C virus and HIV: The challenges of management. Curr hepatitis rep 2006;5:154-161. [DOI: 10.1007/s11901-006-0025-9] [Reference Citation Analysis]
216 Testa R, Testa E, Giannini E, Borro P, Milazzo S, Isola L, Ceppa P, Lantieri PB, Risso D. Noninvasive ratio indexes to evaluate fibrosis staging in chronic hepatitis C: role of platelet count/spleen diameter ratio index. J Intern Med. 2006;260:142-150. [PMID: 16882278 DOI: 10.1111/j.1365-2796.2006.01673.x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 1.8] [Reference Citation Analysis]
217 Crockett SD, Kaltenbach T, Keeffe EB. Do we still need a liver biopsy? Are the serum fibrosis tests ready for prime time? Clin Liver Dis 2006;10:513-34, viii. [PMID: 17162226 DOI: 10.1016/j.cld.2006.08.009] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 0.6] [Reference Citation Analysis]
218 Brady CW, Mchutchison JG, Patel K. Fibrosis markers in hepatitis C. Curr hepatitis rep 2006;5:86-93. [DOI: 10.1007/s11901-006-0010-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
219 Serrano Grau P, Mascaró Galy JM. Metotrexato: actualización en el tratamiento de la psoriasis. Piel 2006;21:358-363. [DOI: 10.1016/s0213-9251(06)72510-2] [Reference Citation Analysis]
220 Kawamoto M, Mizuguchi T, Katsuramaki T, Nagayama M, Oshima H, Kawasaki H, Nobuoka T, Kimura Y, Hirata K. Assessment of liver fibrosis by a noninvasive method of transient elastography and biochemical markers. World J Gastroenterol 2006; 12(27): 4325-4330 [PMID: 16865773 DOI: 10.3748/wjg.v12.i27.4325] [Cited by in CrossRef: 41] [Cited by in F6Publishing: 43] [Article Influence: 2.4] [Reference Citation Analysis]
221 Pockros PJ. Noninvasive markers of fibrosis in chronic hepatitis patients. J Clin Gastroenterol 2006;40:461-3. [PMID: 16825925 DOI: 10.1097/00004836-200607000-00001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
222 Sebastiani G, Alberti A. Non invasive fibrosis biomarkers reduce but not substitute the need for liver biopsy. World J Gastroenterol 2006; 12(23): 3682-3694 [PMID: 16773685 DOI: 10.3748/wjg.v12.i23.3682] [Cited by in CrossRef: 180] [Cited by in F6Publishing: 191] [Article Influence: 10.6] [Reference Citation Analysis]
223 Halfon P, Bourlière M, Pénaranda G, Cacoub P. [Serum markers of non-invasive fibrosis in chronic hepatitis C virus infection]. Rev Med Interne 2006;27:751-61. [PMID: 16815598 DOI: 10.1016/j.revmed.2006.03.037] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
224 Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, S Sulkowski M, Torriani FJ, Dieterich DT, Thomas DL, Messinger D, Nelson M; APRICOT Clinical Investigators. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006;43:1317-25. [PMID: 16729309 DOI: 10.1002/hep.21178] [Cited by in Crossref: 2543] [Cited by in F6Publishing: 2155] [Article Influence: 149.6] [Reference Citation Analysis]
225 Dioguardi N, Grizzi F, Franceschini B, Bossi P, Russo C. Liver fibrosis and tissue architectural change measurement using fractal-rectified metrics and Hurst’s exponent. World J Gastroenterol 2006; 12(14): 2187-2194 [PMID: 16610019 DOI: 10.3748/wjg.v12.i14.2187] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 26] [Article Influence: 1.5] [Reference Citation Analysis]
226 Sebastiani G, Vario A, Guido M, Noventa F, Plebani M, Pistis R, Ferrari A, Alberti A. Stepwise combination algorithms of non-invasive markers to diagnose significant fibrosis in chronic hepatitis C. J Hepatol 2006;44:686-93. [PMID: 16490278 DOI: 10.1016/j.jhep.2006.01.007] [Cited by in Crossref: 197] [Cited by in F6Publishing: 194] [Article Influence: 11.6] [Reference Citation Analysis]
227 Lebensztejn DM, Skiba E, Tobolczyk J, Sobaniec-Lotowska ME, Kaczmarski M. Diagnostic accuracy of serum biochemical fibrosis markers in children with chronic hepatitis B evaluated by receiver operating characteristics analysis. World J Gastroenterol 2005;11:7192-6. [PMID: 16437671 DOI: 10.3748/wjg.v11.i45.7192] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.4] [Reference Citation Analysis]
228 Colli A, Colucci A, Paggi S, Fraquelli M, Massironi S, Andreoletti M, Michela V, Conte D. Accuracy of a predictive model for severe hepatic fibrosis or cirrhosis in chronic hepatitis C. World J Gastroenterol 2005;11:7318-22. [PMID: 16437635 DOI: 10.3748/wjg.v11.i46.7318] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 23] [Article Influence: 1.1] [Reference Citation Analysis]
229 Pinzani M. Non-invasive evaluation of hepatic fibrosis: don't count your chickens before they're hatched. Gut 2006;55:310-2. [PMID: 16474104 DOI: 10.1136/gut.2005.068585] [Cited by in Crossref: 34] [Cited by in F6Publishing: 28] [Article Influence: 2.0] [Reference Citation Analysis]
230 Parkes J, Guha IN, Roderick P, Rosenberg W. Performance of serum marker panels for liver fibrosis in chronic hepatitis C. J Hepatol 2006;44:462-74. [PMID: 16427156 DOI: 10.1016/j.jhep.2005.10.019] [Cited by in Crossref: 173] [Cited by in F6Publishing: 182] [Article Influence: 10.2] [Reference Citation Analysis]
231 Rockey DC, Bissell DM. Noninvasive measures of liver fibrosis. Hepatology 2006;43:S113-20. [PMID: 16447288 DOI: 10.1002/hep.21046] [Cited by in Crossref: 239] [Cited by in F6Publishing: 221] [Article Influence: 14.1] [Reference Citation Analysis]
232 Nunes D, Fleming C, Offner G, O'Brien M, Tumilty S, Fix O, Heeren T, Koziel M, Graham C, Craven DE, Stuver S, Horsburgh CR Jr. HIV infection does not affect the performance of noninvasive markers of fibrosis for the diagnosis of hepatitis C virus-related liver disease. J Acquir Immune Defic Syndr. 2005;40:538-544. [PMID: 16284529 DOI: 10.1097/01.qai.0000184856.31695.bf] [Cited by in Crossref: 79] [Cited by in F6Publishing: 83] [Article Influence: 4.6] [Reference Citation Analysis]
233 Cortez-Pinto H, de Moura MC, Day CP. Non-alcoholic steatohepatitis: from cell biology to clinical practice. J Hepatol 2006;44:197-208. [PMID: 16274837 DOI: 10.1016/j.jhep.2005.09.002] [Cited by in Crossref: 142] [Cited by in F6Publishing: 153] [Article Influence: 8.4] [Reference Citation Analysis]
234 Blanc J, de Ledinghen V, Rosenbaum J. Fibrose hépatique. EMC - Hépatologie 2006;1:1-7. [DOI: 10.1016/s1155-1976(06)31588-4] [Reference Citation Analysis]
235 Cadranel J, Castera L, Cales P. La ponction biopsie du foie dans le diagnostic et la prise en charge des maladies chroniques du foie. Gastroentérologie Clinique et Biologique 2006;30:121-3. [DOI: 10.1016/s0399-8320(06)73126-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
236 Zeng MD, Lu LG, Mao YM, Qiu DK, Li JQ, Wan MB, Chen CW, Wang JY, Cai X, Gao CF, Zhou XQ. Prediction of significant fibrosis in HBeAg-positive patients with chronic hepatitis B by a noninvasive model. Hepatology 2005;42:1437-45. [PMID: 16317674 DOI: 10.1002/hep.20960] [Cited by in Crossref: 116] [Cited by in F6Publishing: 89] [Article Influence: 6.4] [Reference Citation Analysis]
237 Calès P, Oberti F, Michalak S, Hubert-Fouchard I, Rousselet MC, Konaté A, Gallois Y, Ternisien C, Chevailler A, Lunel F. A novel panel of blood markers to assess the degree of liver fibrosis. Hepatology 2005;42:1373-81. [PMID: 16317693 DOI: 10.1002/hep.20935] [Cited by in Crossref: 388] [Cited by in F6Publishing: 329] [Article Influence: 21.6] [Reference Citation Analysis]
238 Kelleher TB, Afdhal N. Assessment of liver fibrosis in co-infected patients. J Hepatol 2006;44:S126-31. [PMID: 16352364 DOI: 10.1016/j.jhep.2005.11.026] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 1.2] [Reference Citation Analysis]
239 Flisiak R, Jaroszewicz J, Łapiński TW, Flisiak I, Prokopowiczi D. Effect of pegylated interferon alpha 2b plus ribavirin treatment on plasma transforming growth factor-β1, metalloproteinase-1, and tissue metalloproteinase inhibitor-1 in patients with chronic hepatitis C. World J Gastroenterol 2005; 11(43): 6833-6838 [PMID: 16425392 DOI: 10.3748/wjg.v11.i43.6833] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.3] [Reference Citation Analysis]
240 Kelleher TB, Afdhal N. Noninvasive assessment of liver fibrosis. Clin Liver Dis 2005;9:667-83, vii. [PMID: 16207570 DOI: 10.1016/j.cld.2005.08.002] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 1.9] [Reference Citation Analysis]
241 Sogni P, Salmon-céron D, Podevin P. Prise en charge des complications de la cirrhose chez les patients VIH co-infectés par une hépatite virale B ou C. La Presse Médicale 2005;34:1579-83. [DOI: 10.1016/s0755-4982(05)84228-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
242 Chevaliez S, Pawlotsky JM. Use of virologic assays in the diagnosis and management of hepatitis C virus infection. Clin Liver Dis 2005;9:371-82, v. [PMID: 16023971 DOI: 10.1016/j.cld.2005.05.009] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 1.5] [Reference Citation Analysis]
243 Lebensztejn DM, Sobaniec-Łotowska ME, Bauer M, Kaczmarski M, Voelker M, Schuppan D. Serum fibrosis markers as predictors of an antifibrotic effect of interferon alfa in children with chronic hepatitis B. Eur J Gastroenterol Hepatol 2005;17:843-8. [PMID: 16003134 DOI: 10.1097/00042737-200508000-00011] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 0.7] [Reference Citation Analysis]
244 Adams LA, Bulsara M, Rossi E, DeBoer B, Speers D, George J, Kench J, Farrell G, McCaughan GW, Jeffrey GP. Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection. Clin Chem. 2005;51:1867-1873. [PMID: 16055434 DOI: 10.1373/clinchem.2005.048389] [Cited by in Crossref: 387] [Cited by in F6Publishing: 412] [Article Influence: 21.5] [Reference Citation Analysis]
245 Halfon P, Bourlière M, Pénaranda G, Deydier R, Renou C, Botta-Fridlund D, Tran A, Portal I, Allemand I, Rosenthal-Allieri A. Accuracy of hyaluronic acid level for predicting liver fibrosis stages in patients with hepatitis C virus. Comp Hepatol. 2005;4:6. [PMID: 16008833 DOI: 10.1186/1476-5926-4-6] [Cited by in Crossref: 95] [Cited by in F6Publishing: 104] [Article Influence: 5.3] [Reference Citation Analysis]
246 Zeremski M, Talal AH. Noninvasive markers of hepatic fibrosis: are they ready for prime time in the management of HIV/HCV co-infected patients? J Hepatol 2005;43:2-5. [PMID: 15922482 DOI: 10.1016/j.jhep.2005.05.007] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 0.8] [Reference Citation Analysis]